Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
Sponsor: Kissei Pharmaceutical Co., Ltd.
Summary
This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25 to 2 mg per day for 17 weeks in patients with advanced PD with levodopa.
Official title: A Late Phase II Clinical Trial of KDT-3594 in Patients With Advanced Parkinson's Disease With Levodopa
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2024-12-16
Completion Date
2026-04
Last Updated
2026-03-03
Healthy Volunteers
No
Conditions
Interventions
KDT-3594
Oral administration
Placebo
Oral administration
Locations (1)
Research Site
Multiple Locations, Japan